Selected Publications


Lee, S. H., Hu, W., Matulay, J. T., Silva, M. V., Owczarek, T. B., Kim, K., Chua, C. W., Barlow, L. J., Kandoth, C., Williams, A. B., Bergren, S. K., Pietzak, E. J., Anderson, C. B., Benson, M. C., Coleman, J. A., Taylor, B. S., Abate-Shen, C., McKiernan, J. M., Al-Ahmadie, H., Solit, D. B., and Shen, M. M. (2018). Tumor evolution and drug response in patient-derived models of bladder cancerCell in press.

Zou,M., Toivanen, R., Mitrofanova, A., Floc'h, N., Hayati, S., Sun, Y., Le Magnen, C., Chester, D., Mostaghel, E.A., Califano, A., Rubin, M.A., Shen, M.M., and Abate-Shen, C. (2017) Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-resistant Prostate Cancer. Cancer Disc. DOI: 10.1158/2159-8290.CD-16-1174. 

Owczarek, T., Kobayashi, T., Ramirez, R., Rong, L., Puzio-Kuter, A., Iyer, G., Teo, M., Sánchez-Vega, F., Wang, J., Schultz, N., Zheng, T., Solit, D., Al-Ahmadie, H., and Abate-Shen, C. (2017)  ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. Cancer Res; 77(4); 1035–46.

Dutta, A., Panja, S., Virk, R., Kim, J., Zott, R., Cremers, S., Golombos, D., Liu, D., Mosquera, J., Mostaghel, E.A., Barbieri, C., Mitrofanova, A., Abate-Shen, C.   Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition. European Urology.

Dutta A., Le Magnen C., Mitrofanova A., Ouyang X., Califano A., Abate-Shen C. (2016) Identification of an NKX3.1-G9a-UTY transcriptional regulatory network that controls prostate differentiation. Science. 352(6293):1576-1580.

Mitrofanova A., Aytes A., Zou M., Shen M.M., *Abate-Shen C., and *Califano A. (2015). Predicting drug response in human prostate cancer from preclinical analysis of in vivo mouse models. Cell Rep. 12: 2060-2071. (*co-corresponding)

Aytes, A., Mitrofanova, A., Lefebvre, C., Alvarez, M.J., Castillo-Martin, M., Zheng, T., Eastham, J.A., Gopalan, A., Pienta, K.J., Shen, M.M., Califano, A., and Abate-Shen, C. (2014). Cross-species analysis of genome-wide regulatory networks identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 25: 638-651.

Irshad, S., Bansal, M., Castillo-Martin, M. Aytes, A., Zheng, T., Wenske, S., Guarnieri, P., Sumazin, P., Le Magnen, C., Benson, M.C., Shen, M.M., Califano, A., and Abate-Shen, C. (2013). A molecular signature predictive of indolent prostate cancer. Sci. Transl. Med. 5:202ra122.

Aytes, A., Mitrofanova, A., Kinkade, C.W., Lefebvre, C., Lei, M., Phelan, V., Le, H.C., Koutcher, J.A., Cardiff, R.D., Califano, A., Shen, M.M., and Abate-Shen, C. (2013). ETV4 promotes metastasis in response to activation of P13 kinase and Ras signaling in a mouse model of advanced prostate cancer. Proc. Natl. Acad. Sci. USA 110:E3506-15.

Kobayashi, T., Wang, J., Al-Ahmadie, H.A., and Abate-Shen, C. (2013). ARF regulates the stability of p16 protein via REGy-dependent proteasome degradation. Mol Cancer Res. 11:828-33.

Delto, J.C., Kobayashi, T., Benson, M.C., McKiernan, J., and Abate-Shen, C. (2013). Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression. Oncotarget 4:269-276.

Wang, Z.A., Mitrofanova, A., Bergen, S.K., Cardiff, R.D., Abate-Shen, C., Califano, A., and Shen, M.M. (2013). Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell of origin model for prostate cancer heterogeneity. Nat. Cell Biol. 15:274-283.

Wang, J., Kobayashi, T., Floc'h, N., Kinkade, C., Aytes, A., Dankort, D., Lefebvre, C., Mitrofanova, A., Cardiff, R., McMahon, M., Califano, A., Shen, M. and Abate-Shen, C. (2012). B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res. 72:4765-4776.

Floc'h, N., Kinkade, C., Kobayashi, T., Aytes, A., Lefebvre, C., Mitrofanova, A., Cardiff, R., Califano, A., Shen, M., and Abate-Shen, C. (2012) Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res. 72:4483-93.

Wang, J., Kumar, R., Biggs, V.J., Lee, H., Chen, Y., Kagey, M.H., Young, R.A., and Abate-Shen, C. (2011). The Msx1 homeoprotein recruits Polycomb to the nuclear periphery during development. Dev. Cell 21:575-588.

Seager, C., Puzio-Kuter, A.M., Patel, T., Jain, S., Cordon-Cardo, C., McKiernan, J., and Abate-Shen, C. (2009) Intravesical delivery of Rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev. Res. 2:1008-1014.

Wang, X., Kruithof-de Julio, M., Economides, K.D., Walker, D., Yu, H., Halili, M.V., Hu, Y., Price, S., Abate-Shen, C., and Shen, M.M. (2009). A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461: 495-500.

Puzio-Kuter, A.M., Castillo-Martin, M., Kinkade C.W., Wang, X., Shen, T.H., Matos, T., Sun, Y., Shen, M.M., Cordon-Cardo, C., and Abate-Shen, C. (2009) Inactivation of p53 and Pten promotes invasive bladder. Genes Dev. 23:675-680.

Kinkade, C.W., Castillo-Martin, M., Puzio-Kuter, A., Yan, J., Foster, T.H., Gao, H., Sun, Y., Ouyang, X., Gerald, W.L., Cordon-Cardo, C., and Abate-Shen, C. (2008). Targeting Akt/TOR and Erk MAPK signaling inhibits hormone-refractory prostate cancer in a pre-clinical mouse model. J. Clin. Invest. 118:3051-3064.

Ouyang, X., Jessen, W.J., Al-Ahmadie, H., Serio, A.M., Lin, Y., Shih, W.J., Shen, M.M., Aronow, B.J., Vickers, A.J., Gerald, W., and Abate-Shen, C. (2008) Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res. 68:2132-2144.

Banach-Petrosky, W., Jessen, W.J., Ouyang, X., Gao, H., Rao, J., Quinn, J., Aronow, B.J., and Abate-Shen, C. (2007) Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Res. 67:9089-9096.

Gao, H., Ouyang, X., Banach-Petrosky, W.A., Gerald, W.L., Shen, M.M., and Abate-Shen, C. (2006). Combinational activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc. Natl. Acad. Sci. USA 103:14477-14482.

Gao, H., Ouyang, X., Banach-Petrosky, W.A., Shen, M.M., and Abate-Shen, C. (2006). Emergence of androgen-independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. Cancer Res. 66:7929-7933.

Abate-Shen, C., Banach-Petrosky, W.A., Sun, X., Economides, K.D., Desai, N., Gregg, J.P., Borowsky, A.D., Cardiff, R.D., and Shen, M.M. (2003). Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res. 63:3886-3890.

Kim, M., Cardiff, R., Desai, N., Banach-Petrosky, W.A., Parsons, R., Shen, M.M., and Abate-Shen, C. (2002). Cooperativity of Nkx3.1 and Pten loss-of-function in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. USA 99:2884-2889.

Bhatia-Guar, R., Donjacour, A.A., Sciavolino, P. J., Kim, M., Desai, N., Young, P., Norton, C., Gridley, T., Cardiff, R.D., Cunha, G. R., Abate-Shen, C., and Shen, M.M. (1999). Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 13: 966-977.

Review Articles

Arriaga, J.M. and Abate-Shen, C. (2018). Genetically-engineered mouse models of prostate cancer in the post-genomic era. Cold Spring Harbor, in press.

Le Magnen, C. *Shen, MM, and *Abate-Shen, C. (2018). Lineage plasticity in cancer progression and treatment. Annual Reviews: Cancer Biology. in press. (*co-corresponding)

Le Magnen, C., Dutta, A., and Abate-Shen, C. (2016). Optimizing mouse models for precision cancer prevention. Nat. Rev. Cancer 16: 187-196.

Kobayashi, T., Owczarek, T.B., McKiernan, J.M., and Abate-Shen, C. (2015). Modeling bladder cancer in mice: opportunities and challenges. Nat. Rev. Cancer 15: 42-54.

Irshad, S. and Abate-Shen, C. (2013). Modeling prostate cancer in mice: Something old, something new, something premalignant, something metastatic. Cancer Metastases Rev. 32:109-22.

Seager, C., Puzio-Kuter, A.M., Cordon-Cardo, C., McKiernan, J., and Abate-Shen, C. (2010). Mouse models of human bladder cancer as a tool for drug discovery. Curr. Protoc. Pharmacol. 14.14.1-14.14.18.

Shen, M.M., and Abate-Shen, C. (2010). Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 24: 1967-2000.

Abate-Shen, C., Shen, M.M., and Gelmann, E. (2008). Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation. 76: 717-727.

Shen, M.M. and Abate-Shen, C. (2007). Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res. 67:6535-6538.

Abate-Shen, C. (2002). Deregulated homeobox gene expression in cancer: cause or consequence? Nat. Rev. Cancer 2: 777-785.

Abate-Shen, C., and Shen, M. M. (2000). Molecular genetics of prostate cancer. Genes Dev. 14: 2410-2434.